AKEBIA THERAPEUTICS, INC. Accounts Receivable, Allowance for Credit Loss
AKEBIA THERAPEUTICS, INC. (AKBA) had Accounts Receivable, Allowance for Credit Loss of $2.89 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-05
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $2.89M.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $2.89M.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $2.69M.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $2.60M.
| Period end | Accounts Receivable, Allowance for Credit Loss | Accounts Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2026-06-30 | $2.89M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $2.89M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $2.69M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $2.60M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $1.91M 10-Q · filed 2026-05-07 | $1.91M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.21M 10-Q · filed 2026-08-05 | $1.21B 10-K · filed 2025-03-13 |
| 2024-09-30 | $528.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $184.00K 10-Q · filed 2025-08-07 | $200.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $578.00K 10-Q · filed 2025-05-08 | $600.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.03M 10-K · filed 2026-02-26 | $1.00M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $544.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.11M 10-K · filed 2026-02-26 | |
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-26 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |